Phaseline

Companies › Aligos Therapeutics

Aligos Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 2, 1 Phase 1; Infectious disease, Other; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ALG-000184
Nucleotide reverse transcriptase inhibitor (NrtI)
–Phase 2Chronic Hepatitis B Infection; Healthy VolunteerMar 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06672900ALG-000184Phase 1Healthy VolunteerOtherJul 2025
NCT06963710ALG-000184Phase 2Chronic Hepatitis B InfectionInfectious diseaseMar 2027

From the company's SEC filings

Cash and short-term investments of $31m on 2026-09-30; operating cash outflow about $63m a year; runway about 6 months at that burn, to Mar 2027; 1 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Private offerings reported to the SEC (Form D)

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 2 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Freya Biosciences ApS Avenue Therapeutics BioAegis Therapeutics Lakewood-Amedex 60 Degrees Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.